Corrigendum to “Antisense Oligonucleotide Mediated Splice Correction of a Deep Intronic Mutation in OPA1” (Molecular Therapy - Nucleic Acids (2016) 5(e390)(S2162253117301130)(10.1038/mtna.2016.93));Antisense Oligonucleotide Mediated Splice Correction of a Deep Intronic Mutation in OPA1

Molecular Therapy Nucleic Acids

Volumn 5, Issue , 2016, Pages e390-

  Bonifert, Tobias ^a   Gonzalez Menendez, Irene ^a   Battke, Florian ^b   Theurer, Yvonne ^c,d   Synofzik, Matthis ^c,d   Schöls, Ludger ^c,d   Wissinger, Bernd ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b CEGAT GMBH   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

antisense oligonucleotides; deep intronic mutation; OPA1; optic neuropathies; splice correction

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA ACTIN; CEP128 PROTEIN; CHAPERONIN 60; FAM21FP PROTEIN; MESSENGER RNA PRECURSOR; OPA1 PROTEIN; PROTEIN; RNU6 42P PROTEIN; SCGB1D1 PROTEIN; SNORA51 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL EVALUATION; CONCENTRATION PROCESS; CONTROLLED STUDY; DISEASE ASSOCIATION; FIBROBLAST; GENE MUTATION; GENETIC TRANSFECTION; HAPLOINSUFFICIENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; OPTIC NERVE DISEASE; PRIORITY JOURNAL; PROTEIN SPLICING; PYROSEQUENCING; RNA SPLICING; THERAPY EFFECT; WESTERN BLOTTING;

EID: 85015617443     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2016.106     Document Type: Erratum

References (38)

1. 1 Alexander, C, Votruba, M, Pesch, UE, Thiselton, DL, Mayer, S, Moore, A, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet 26 (2000), 211–215.
2. 2 Delettre, C, Lenaers, G, Griffoin, JM, Gigarel, N, Lorenzo, C, Belenguer, P, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 26 (2000), 207–210.
3. 3 Anikster, Y, Kleta, R, Shaag, A, Gahl, WA, Elpeleg, O, Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews. Am J Hum Genet 69 (2001), 1218–1224.
4. 4 Hanein, S, Perrault, I, Roche, O, Gerber, S, Khadom, N, Rio, M, et al. TMEM126A, encoding a mitochondrial protein, is mutated in autosomal-recessive nonsyndromic optic atrophy. Am J Hum Genet 84 (2009), 493–498.
5. 5 Metodiev, MD, Gerber, S, Hubert, L, Delahodde, A, Chretien, D, Gérard, X, et al. Mutations in the tricarboxylic acid cycle enzyme, aconitase 2, cause either isolated or syndromic optic neuropathy with encephalopathy and cerebellar atrophy. J Med Genet 51 (2014), 834–838.
6. 6 Inoue, H, Tanizawa, Y, Wasson, J, Behn, P, Kalidas, K, Bernal-Mizrachi, E, et al. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 20 (1998), 143–148.
7. 7 Chaussenot, A, Rouzier, C, Quere, M, Plutino, M, Ait-El-Mkadem, S, Bannwarth, S, et al. Mutation update and uncommon phenotypes in a French cohort of 96 patients with WFS1-related disorders. Clin Genet 87 (2015), 430–439.
8. 8 Angebault, C, Guichet, PO, Talmat-Amar, Y, Charif, M, Gerber, S, Fares-Taie, L, et al. Recessive mutations in RTN4IP1 cause isolated and syndromic optic neuropathies. Am J Hum Genet 97 (2015), 754–760.
9. 9 Elachouri, G, Vidoni, S, Zanna, C, Pattyn, A, Boukhaddaoui, H, Gaget, K, et al. OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution. Genome Res 21 (2011), 12–20.
10. 10 Frezza, C, Cipolat, S, Martins de Brito, O, Micaroni, M, Beznoussenko, GV, Rudka, T, et al. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 126 (2006), 177–189.
11. 11 Cipolat, S, Martins de Brito, O, Dal Zilio, B, Scorrano, L, OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci USA 101 (2004), 15927–15932.
12. 12 Marchbank, NJ, Craig, JE, Leek, JP, Toohey, M, Churchill, AJ, Markham, AF, et al. Deletion of the OPA1 gene in a dominant optic atrophy family: evidence that haploinsufficiency is the cause of disease. J Med Genet, 39, 2002, e47.
13. 13 Yu-Wai-Man, P, Griffiths, PG, Burke, A, Sellar, PW, Clarke, MP, Gnanaraj, L, et al. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology, 117, 2010, 1538 46, 1546.e1.
14. 14 Bonifert, T, Karle, KN, Tonagel, F, Batra, M, Wilhelm, C, Theurer, Y, et al. Pure and syndromic optic atrophy explained by deep intronic OPA1 mutations and an intralocus modifier. Brain 137:Pt 8 (2014), 2164–2177.
15. 15 Sharma, VK, Watts, JK, Oligonucleotide therapeutics: chemistry, delivery and clinical progress. Future Med Chem 7 (2015), 2221–2242.
16. 16 Anderson, KP, Fox, MC, Brown-Driver, V, Martin, MJ, Azad, RF, Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob Agents Chemother 40 (1996), 2004–2011.
17. 17 Crooke, RM, Graham, MJ, Lemonidis, KM, Whipple, CP, Koo, S, Perera, RJ, An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 46 (2005), 872–884.
18. 18 Voit, T, Topaloglu, H, Straub, V, Muntoni, F, Deconinck, N, Campion, G, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 13 (2014), 987–996.
19. 19 Mendell, JR, Goemans, N, Lowes, LP, Alfano, LN, Berry, K, Shao, J, et al., Eteplirsen Study Group and Telethon Foundation DMD Italian Network, Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79 (2016), 257–271.
20. 20 Collin, RW, den Hollander, AI, van der Velde-Visser, SD, Bennicelli, J, Bennett, J, Cremers, FP, Antisense oligonucleotide (AON)-based therapy for Leber congenital amaurosis caused by a frequent mutation in CEP290. Mol Ther Nucleic Acids, 1, 2012, e14.
21. 21 Gerard, X, Perrault, I, Hanein, S, Silva, E, Bigot, K, Defoort-Delhemmes, S, et al. AON-mediated exon skipping restores ciliation in fibroblasts harboring the common Leber congenital amaurosis CEP290 mutation. Mol Ther Nucleic Acids, 1, 2012, e29.
22. 22 Piotrovskii, VK, Pharmacokinetic stochastic model with Weibull-distributed residence times of drug molecules in the body. Eur J Clin Pharmacol 32 (1987), 515–523.
23. 23 Carrasco, RA, Stamm, NB, Marcusson, E, Sandusky, G, Iversen, P, Patel, BK, Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 10 (2011), 221–232.
24. 24 Aartsma-Rus, A, De Winter, CL, Janson, AA, Kaman, WE, Van Ommen, GJ, Den Dunnen, JT, et al. Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides 15 (2005), 284–297.
25. 25 Singh, NK, Singh, NN, Androphy, EJ, Singh, RN, Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 26 (2006), 1333–1346.
26. 26 Bassi, E, Falzarano, S, Fabris, M, Gualandi, F, Merlini, L, Vattemi, G, et al. Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice. J Biomed Biotechnol, 2012, 2012, 897076.
27. 27 Gérard, X, Perrault, I, Munnich, A, Kaplan, J, Rozet, JM, Intravitreal injection of splice-switching oligonucleotides to manipulate splicing in retinal cells. Mol Ther Nucleic Acids, 4, 2015, e250.
28. 28 Garanto, A, Chung, DC, Duijkers, L, Corral-Serrano, JC, Messchaert, M, Xiao, R, et al. In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery. Hum Mol Genet, 2016 epub ahead of print.
29. 29 Singh, NN, Lee, BM, Singh, RN, Splicing regulation in spinal muscular atrophy by an RNA structure formed by long-distance interactions. Ann NY Acad Sci 1341 (2015), 176–187.
30. 30 Zalachoras, I, Evers, MM, van Roon-Mom, WM, Aartsma-Rus, AM, Meijer, OC, Antisense-mediated RNA targeting: versatile and expedient genetic manipulation in the brain. Front Mol Neurosci, 4, 2011, 10.
31. 31 Garanto, A, van Beersum, SE, Peters, TA, Roepman, R, Cremers, FP, Collin, RW, Unexpected CEP290 mRNA splicing in a humanized knock-in mouse model for Leber congenital amaurosis. PLoS One, 8, 2013, e79369.
32. 32 Aartsma-Rus, A, van Vliet, L, Hirschi, M, Janson, AA, Heemskerk, H, de Winter, CL, et al. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 17 (2009), 548–553.
33. 33 Zuker, M, Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31 (2003), 3406–3415.
34. 34 Hofacker, IL, Vienna RNA secondary structure server. Nucleic Acids Res 31 (2003), 3429–3431.
35. 35 Desmet, FO, Hamroun, D, Lalande, M, Collod-Béroud, G, Claustres, M, Béroud, C, Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res, 37, 2009, e67.
36. 36 Langmead, B, Trapnell, C, Pop, M, Salzberg, SL, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol, 10, 2009, R25.
37. 37 Stemmer, M, Thumberger, T, Del Sol Keyer, M, Wittbrodt, J, Mateo, JL, CCTop: an intuitive, flexible and reliable CRISPR/Cas9 target prediction tool. PLoS One, 10, 2015, e0124633.
38. 38 Aartsma-Rus, A, Kaman, WE, Bremmer-Bout, M, Janson, AA, den Dunnen, JT, van Ommen, GJ, et al. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther 11 (2004), 1391–1398.